Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations

Journal of Immunotherapy

Volumn 36, Issue 4, 2013, Pages 223-237

  Schick, Julia ^a   Vogt, Valentin ^a   Zerwes, Marion ^b   Kroell, Tanja ^a   Kraemer, Doris ^c   Köhne, Claus Henning ^c   Hausmann, Andreas ^a   Buhmann, Raymund ^a,b   Tischer, Johanna ^a   Schmetzer, Helga ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c Municipal Hospital   (Germany)

Author keywords

AML; dendritic cells; immune escape; regulatory T cells

Indexed keywords

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; CELL DIFFERENTIATION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84876786701     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31829180e7     Document Type: Article

References (64)

1. Giles FJ. New drugs in acute myeloid leukemia. Curr Oncol Rep. 2002;5:369-374.
2. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc. 2006;2:247-260. (Pubitemid 43205780)
3. Scholl N, Loibl J, Kremser A, et al. The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders. Leuk Lymphoma. 2009;3:427-436.
4. Tait BD. HLA class I expression on human cancer cells. Implications for effective immunotherapy. Hum Immunol. 2000;2:158-165. (Pubitemid 30075238)
5. van Luijn MM, van den Ancker W, Chamuleau ME, et al. Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia. Immunotherapy. 2010;1:85-97.
6. Cormier JN, Panelli MC, Hackett JA, et al. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer. 1999;5:781-790. (Pubitemid 29066293)
7. Salih HR, Schmetzer HM, Burke C, et al. Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J Immunol. 2001;7:4059-4066. (Pubitemid 32910853)
8. + regulatory T cells by continuous antigen stimulation. J Leukoc Biol. 2008;5: 1111-1117. (Pubitemid 351960342)
9. +CD25 high regulatory cells in human peripheral blood. J Immunol. 2001;3:1245-1253. (Pubitemid 32703119)
10. Lindley S, Dayan CM, Bishop A, et al. Defective suppressor function in CD4+(+)CD25+(+) T-cells from patients with type 1 diabetes. Diabetes. 2005;1:92-99. (Pubitemid 40105099)
11. Bladon J, Taylor PC. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br J Haematol. 1999; 4:707-711. (Pubitemid 30020139)
12. Zhang H, Podojil JR, Chang J, et al. TGF-beta-induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis. J Immunol. 2010;12:6629-6636.
13. + regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J Immunol. 2007;7:4685-4693.
14. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;1:20-21. (Pubitemid 32044513)
15. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;1: 18-20. (Pubitemid 32044512)
16. Zhou Q, Bucher C, Munger ME, et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 2009;18:3793-3802.
17. Szczepanski MJ, Szajnik M, Czystowska M, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 2009; 10:3325-3332.
18. Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in cancer. Adv Cancer Res. 2010;57-117.
19. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;3:1151-1164.
20. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;5609:1057-1061. (Pubitemid 36222930)
21. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330-336. (Pubitemid 36432314)
22. Corthay A. How do regulatory T cells work? Scand J Immunol. 2009;4:326-336.
23. Pyzik M, Piccirillo CA. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leukoc Biol. 2007;2:335-346. (Pubitemid 47230645)
24. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4+(+)CD25+(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;5:629-644. (Pubitemid 32844773)
25. Grossman WJ, Verbsky JW, Barchet W, et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;4:589-601. (Pubitemid 39370513)
26. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007; 4:1225-1232. (Pubitemid 47281420)
27. 0-adenosine monophosphate to adenosine. J Immunol. 2006;10:6780-6786. (Pubitemid 44715042)
28. Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;12:1206-1212. (Pubitemid 37547898)
29. Schmetzer HM. Antileukemic T-cell-mediated immune reactions: limitations and perspectives for future therapies. Immunotherapy. 2011;7:809-811.
30. Grabrucker C, Liepert A, Dreyig J, et al. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells. J Immunother. 2010;5: 523-537.
31. Liepert A, Grabrucker C, Kremser A, et al. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. Cell Immunol. 2010;1:23-30.
32. Kremser A, Dressig J, Grabrucker C, et al. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J Immunother. 2010;2:185-199.
33. Dreyssig J, Kremser A, Liepert A, et al. Various "dendritic cell antigens" are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes. Immuno-therapy. 2011;9:1113-1124.
34. Schmetzer HM, Kremser A, Loibl J, et al. Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia. 2007;6: 1338-1341. (Pubitemid 46831833)
35. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4+(+)CD25+(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002; 10:3493-3499. (Pubitemid 34534513)
36. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144-1150. (Pubitemid 37173698)
37. Hoffmann P, Ermann J, Edinger M, et al. Donor-type CD4+(+)CD25+(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;3:389-399. (Pubitemid 34875667)
38. Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003; 4:243-256. (Pubitemid 40045611)
39. Trenado A, Charlotte F, Fisson S, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003;11:1688-1696. (Pubitemid 38063726)
40. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;3:804-811. (Pubitemid 44154611)
41. Sancho D, Gomez M, Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 2005;3:136-140. (Pubitemid 40312520)
42. Nguyen XD, Eichler H, Dugrillon A, et al. Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. J Immunol Methods. 2003;1-2:57-68. (Pubitemid 36351542)
43. Xue HH, Kovanen PE, Pise-Masison CA, et al. IL-2 negatively regulates IL-7 receptor alpha chain expression in activated T lymphocytes. Proc Natl Acad Sci U S A. 2002;21: 13759-13764. (Pubitemid 35215454)
44. Foxwell BM, Taylor-Fishwick DA, Simon JL, et al. Activation induced changes in expression and structure of the IL-7 receptor on human T cells. Int Immunol. 1992;2:277-282.
45. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;7:490-500.
46. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;6: 899-911.
47. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;7:1701-1711. (Pubitemid 44036276)
48. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;7:1693-1700. (Pubitemid 44036275)
49. Hartigan-O'Connor DJ, Poon C, Sinclair E, et al. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods. 2007;1-2:41-52. (Pubitemid 46110995)
50. Wang X, Zheng J, Liu J, et al. Increased population of CD4+(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol. 2005;6:468-476. (Pubitemid 41687780)
51. Shenghui Z, Yixiang H, Jianbo W, et al. Elevated frequencies of CD4 CD25 CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 2010;6:1373-1381.
52. Smith TR, Kumar V. Revival of CD8+ Treg-mediated suppression. Trends Immunol. 2008;7:337-342.
53. Wang RF. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum Immunol. 2008; 11:811-814.
54. Joosten SA, van Meijgaarden KE, Savage ND, et al. Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci U S A. 2007;19:8029-8034. (Pubitemid 47185870)
55. Wei S, Kryczek I, Zou L, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005;12:5020-5026. (Pubitemid 40827308)
56. Chaput N, Louafi S, Bardier A, et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut. 2009;4:520-529.
57. Kleinewietfeld M, Puentes F, Borsellino G, et al. CCR6 expression defines regulatory effector/memory-like cells within the CD25+(+)CD4+ T-cell subset. Blood. 2005;7: 2877-2886. (Pubitemid 40446282)
58. Seddiki N, Santner-Nanan B, Tangye SG, et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood. 2006;7:2830-2838.
59. Valmori D, Merlo A, Souleimanian NE, et al. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest. 2005;7:1953-1962. (Pubitemid 40979735)
60. Hasko G, Linden J, Cronstein B, et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;9:759-770.
61. Andre S, Tough DF, Lacroix-Desmazes S, et al. Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol. 2009;5:1575-1587.
62. Tang Q, Boden EK, Henriksen KJ, et al. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol. 2004;11:2996-3005. (Pubitemid 39549379)
63. Yamazaki S, Inaba K, Tarbell KV, et al. Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity. Immunol Rev. 2006;314-329. (Pubitemid 44116717)
64. Mahic M, Henjum K, Yaqub S, et al. Generation of highly suppressive adaptive CD8+(+)CD25+(+)FOXP3+(+) regulatory T cells by continuous antigen stimulation. Eur J Immunol. 2008;3:640-646.